tweetindex
EN

NICE

@NICEComms · London and Manchester, UK · joined 27 Oct 2009

Official feed of NICE - National Institute for Health and Care Excellence. We produce evidence-based health and social care guidance. Tweets by the comms team.

236 566Followers
1 093Following
17 312Posts total
36.9KViews on collected posts

Latest posts

Jimi was one of the first people to receive CRISPR gene therapy, a treatment that NICE recommended for use on the NHS in England in 2025. Read Jimi's story: https://t.co/0uMh5hRg64 #SickleCellAwarenessMonth #SickleCellMonth https://t.co/4xnO5lkaZm
Quote from Jimi Olaghere, one of the first people in the world to receive CRISPR gene therapy. Jimi says, Life was bleak. Very, very dark, hopeless. Life's good now, so much better than before.
1.8K views · 4 likes · 0 reposts · 1 replies Open on X →
Many people with OCD and BDD live with symptoms for years before receiving the right support. Draft NICE guidance aims to help healthcare professionals identify these conditions earlier and offer more personalised care. Share your views: https://t.co/qdC1ZBoFxR https://t.co/IzM
Healthcare professional in consultation with patient. Overlaid text reads: New draft guidance aims to improve identification of OCD and body dysmorphic disorder - Consultation now open
1.7K views · 0 likes · 0 reposts · 0 replies Open on X →
NICE recommends Enhertu for people with HER2-low advanced breast cancer. Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use. Learn more: https://t.co/hMe78NkWbS 4.4K views · 7 likes · 5 reposts · 1 replies Open on X →
Around 200 children and young people with rare nerve tumours are set to benefit after we published final guidance recommending a new treatment today. Mirdametinib is an option for some families when surgery isn't possible. Find out more: https://t.co/uhhVsM6ARL https://t.co/K
0:09
2.1K views · 3 likes · 1 reposts · 0 replies Open on X →
NICE has completed the first test of a new approach to keeping guidance aligned and up-to-date. Using evidence from our updated type 2 diabetes guideline, we've updated recommendations for 4 medicines through our whole lifecycle approach programme: https://t.co/lLoMOFThbM https:
Keeping NICE guidance up-to-date - First pilot aligns technology appraisals with updated type diabetes guidance
Professional photo of Jeanette Kusel, NICE’s senior responsible officer for the Whole Lifecycle Approach programme. Quote reads "This pilot shows we can keep technology appraisals aligned with clinical guidelines more efficiently, without compromising the rigour or transparency that NICE decisions depend on. 
It's an important first step as we look to apply this approach more widely over the coming year."
4.8K views · 16 likes · 5 reposts · 0 replies Open on X →
Find out about our priorities and work in health and social care at this month’s public board meeting. Register here: https://t.co/5wxhDYQ1WV https://t.co/zn47FkFGRs 2.1K views · 0 likes · 0 reposts · 0 replies Open on X →
"No one can understand the process as well as a patient." Debra survived a heart attack at 38 and joined a NICE committee as a lay member to help shape our digital cardiac rehabilitation guidance. Patient perspective is at the heart of everything we do: https://t.co/Af5oqCnWw7 3.9K views · 7 likes · 3 reposts · 0 replies Open on X →
We've published our EQ-5D-5L interim methods statement, ahead of a full modular update later this year. The statement sets out key elements of the updated methods and implementation approach to support transition to the new value set. Learn more: https://t.co/iTwU2w420T 2.1K views · 2 likes · 4 reposts · 2 replies Open on X →
Children and young people aged 5 to 17 with severe allergies caused by tree pollen could benefit from a targeted daily treatment after NICE published final guidance recommending betula verrucosa (Itulazax 12 SQ-Bet) Find out more ⬇️ https://t.co/wMODjACWzO https://t.co/FVBGIFvc8 4.8K views · 8 likes · 5 reposts · 1 replies Open on X →
More children with severe allergies caused by house dust mites could benefit from a targeted daily treatment after NICE published final guidance recommending 12 SQ-HDM SLIT for children aged 5 to 11. Find out more⬇️ https://t.co/sakrR8ryLz https://t.co/4gjW4eJxmv 2.7K views · 2 likes · 2 reposts · 1 replies Open on X →
The decision has been welcomed by @Cardiomyopathy, who said they were delighted a treatment that could make a considerable difference to people’s day-to-day lives will soon be available on the NHS. https://t.co/G5l6T7CxCr 415 views · 0 likes · 0 reposts · 0 replies Open on X →
@MHRAgovuk said the decision highlights how closer collaboration can help patients access innovative treatments sooner. https://t.co/3sje2G2dDp 2.1K views · 1 likes · 0 reposts · 1 replies Open on X →
Today’s guidance was published two weeks faster thanks to closer working between NICE and @MHRAgovuk. https://t.co/VHHGKVpflO 347 views · 0 likes · 0 reposts · 1 replies Open on X →
Thousands of people with a serious heart condition could benefit from a new treatment, with NICE publishing final guidance on aficamten on the same day it received approval from @MHRAgovuk. Find out more 👇 https://t.co/Clfn6Fm0hV https://t.co/muUjrpU3je 3.6K views · 6 likes · 3 reposts · 4 replies Open on X →

Against accounts of the same size

14 posts from the last 90 days, next to the 100K–1M follower range. below its peers on both reach and engagement.

Median views2 116this account5 983median for 100K–1M
Reach, %0.89%this account1.49%median for 100K–1M
Engagement, %0.26%this account0.93%median for 100K–1M
MetricThis accountMedian for 100K–1MRatio
Median views per post2 1165 9830.35×
Reach (views ÷ followers)0.89%1.49%0.60×
Engagement rate0.26%0.93%0.28×

Others in this range →   Compare with another account →   How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

3.6K30 Jul
347
2.1K
415
2.7K26 Aug
4.8K
2.1K27 Aug
3.9K1 Sep
2.1K
4.8K15 Sep
2.1K16 Sep
4.4K17 Sep
1.7K
1.8K18 Sep

Last 14 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.45%30 Jul
0.29%
0.15%
0.00%
0.18%26 Aug
0.29%
0.38%27 Aug
0.26%1 Sep
0.00%
0.46%15 Sep
0.19%16 Sep
0.29%17 Sep
0.00%
0.27%18 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 0.93%.

What the audience does

Likes50.0%56 in total
Reposts25.0%28 in total
Replies10.7%12 in total
Quotes4.5%5 in total
Bookmarks9.8%11 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Similar accounts